sellWeak10b5-1 plan
Michael Halstead sold $3.7M of ITCI
President at Intra-Cellular Therapies, Inc.. 41,583 shares at an average of $88.79, traded Nov 12, 2024, filed Nov 14, 2024.
Warning score
30Value
$3.7M
41,583 shares
Holdings after
0
-182% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RolePresident
- +25Trade size$3.7M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-127275, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | MOption exercise Common Stock10b5-1 | +22,869 | $23.94 | $547k | 22,869 | Nov 14, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock10b5-1 | -15,105 | $88.72 | $1.3M | 7,764 | Nov 14, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock10b5-1 | -6,116 | $89.63 | $548k | 1,648 | Nov 14, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock10b5-1 | -1,648 | $90.89 | $150k | 0 | Nov 14, 2024 |
| Nov 13, 2024 | MOption exercise Common Stock10b5-1 | +18,714 | $36.89 | $690k | 18,714 | Nov 14, 2024 |
| Nov 13, 2024 | SOpen-market sale Common Stock10b5-1 | -13,371 | $88.17 | $1.2M | 5,343 | Nov 14, 2024 |
| Nov 13, 2024 | SOpen-market sale Common Stock10b5-1 | -5,343 | $88.92 | $475k | 0 | Nov 14, 2024 |
| Nov 12, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -22,869 | $0.00 | $0 | 0 | Nov 14, 2024 |
| Nov 13, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -18,714 | $0.00 | $0 | 0 | Nov 14, 2024 |
Related signals
Other insiders at Intra-Cellular Therapies, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $8.7M 102,697 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.